%0 Journal Article
%T A review of generic medicine pricing in Europe
%A Professor Steven Simoens
%A MSc
%A PhD
%J Generics and Biosimilars Initiative Journal
%D 2012
%I Pro Pharma Communications International
%X Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is to review generic medicine pricing in Europe by analysing the factors that influence them.Methods: The literature review focused on selected studies that highlighted generic medicine pricing in ambulatory care in Europe. PubMed, the Centre for Reviews and Dissemination databases, Cochrane Database of Systematic Reviews, and EconLit were searched up to August 2011. Search terms included, ¡®pharmaceuticals¡¯, ¡®generic medicines¡¯, ¡®Europe¡¯, ¡®pricing¡¯, ¡®discount¡¯, and ¡®rebate¡¯. Bibliographies of included studies were checked for relevant studies and the status of generic medicines pricing in Europe was also documented via accessing the European Generic medicines Association market survey.Results: Ex-manufacturer prices for generic medicines were found to vary substantially between European countries, which suggests that pricing not only reflects production costs, but is also influenced by the domestic regulatory environment. The penetration of generic medicines is more successful in countries that permit free pricing of medicines than in those that have price regulation. Although tendering systems may reduce (generic) medicine prices in the short term, little is known about the overall long-term impact of such systems.Conclusion: No single approach towards developing generic medicine pricing policies and attaining cost savings was evident.
%K Europe
%K generic medicines
%K pharmaceutical policy
%K pricing
%U http://gabi-journal.net/a-review-of-generic-medicine-pricing-in-europe.html